Results 91 to 100 of about 16,304 (256)
Biosimilars: How similar or dissimilar are they? (Review Article) [PDF]
, 2006 Simon D. Roger
openalex +1 more source
The Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to GH
Clinical Endocrinology, EarlyView.ABSTRACT Introduction Recombinant human growth hormone (GH) therapy shows variable growth responses in patients with growth hormone deficiency (GHD), highlighting the need for reliable biomarkers to predict individual sensitivity. Objective This study investigated circulating microRNAs (miRNAs) involved in growth plate regulation during GH therapy in ...
Caroline Rosa Pellicciari +8 more
wiley +1 more source
Biosimilar medicines uptake: The role of the clinical pharmacist
Exploratory Research in Clinical and Social Pharmacy, 2021 The introduction of biological medicines has revolutionized the management of chronic diseases. Due to the high cost of biological medicine coupled with the fact that patents of many of these medicines are on the verge of expiration, manufacturers are ...
Roland Nnaemeka Okoro
doaj
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
Gastroenterology Review, 2019 Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis.
Magdalena Kaniewska +6 more
doaj +1 more source
BiologicsUstekinumab is a fully human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 subunit of interleukins (IL-) 12 and 23, inhibiting their activity by preventing binding to their receptors. The European extension of the patent (Supplementary Protection Certificate) of ustekinumab expired on July 20, 2024.
Elena Carmona-Rocha, Lluís Puig
openaire +2 more sources
Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang +8 more
wiley +1 more source
Monoclonal antibody biosimilars for cancer treatment
iScienceSummary: Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies.
Linda N. Broer +6 more
doaj
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Background The study objective was to compare the effectiveness of adalimumab (ADA) in monotherapy and in combination with methotrexate (MTX) for paediatric noninfectious uveitis (NIU). Methods Registry‐based observational study. Children receiving ADA for active uveitis were divided into the ADA monotherapy group (group 1) and the ADA plus ...
Carla Gaggiano +40 more
wiley +1 more source